Oncology Pharmacy in Focus: BCOP Preconference by AVAHO and HOPA
Originally presented as a BCOP Pre-Conference at AVAHO's 2025 Annual Meeting, this curated program features three sessions totaling four hours of Board-Certified Oncology Pharmacist (BCOP) continuing education (CE) credits.
Presenters, Descriptions, and Learning Objectives
UAN#: 0465-0000-25-128-H01-P
Presenters:
- Alyson Clough
- Paige May
- Kendall Shultes
Description:
This in-depth session on managing relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) and Multiple Myeloma (MM) will highlight sequencing data and specific treatment considerations for cytotoxic chemotherapy options, hematopoietic stem cell transplantation (HSCT) and novel chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager therapies. This session aims to enhance your ability to utilize available evidence and provide personalized care when sequencing therapy in relapsed/refractory settings.
Learning Objectives:
- Review historical chemotherapy treatment options for relapsed/refractory diffuse large B-cell lymphoma and multiple myeloma.
- Recognize novel treatment options for relapsed/refractory diffuse large B-cell lymphoma and multiple myeloma.
- Examine uncertainties in sequencing treatment pathways for relapsed/refractory diffuse large B-cell lymphoma and multiple myeloma.
- Compare key differences between treatment modalities including practical considerations, toxicities and patient outcomes.
- Identify available literature for sequencing treatment options in relapsed/refractory diffuse large B-cell lymphoma and multiple myeloma.
- Develop personalized treatment plans based on patient cases to apply unique clinical characteristics.
UAN#: 0465-0000-25-129-H05-P
Presenters:
- Emily Hennes
- Steve Bartlett
Description:
This session will explore key clinical trial designs, including adaptive, basket, and decentralized, the role of cooperative groups in advancing cancer research, and best practices for collaborating with research teams. Attendees will gain insights into optimizing medication management, ensuring protocol adherence, and supporting patient safety in clinical trials.
Learning Objectives:
- Describe current trends in oncology clinical trials and drug approvals
- Distinguish conventional and modern clinical trial designs
- Recognize the role of cooperative groups in cancer clinical research
- Identify challenges in providing pharmacy care for clinical trial patients
- Discuss best practices for collaborating with research teams
- Apply strategies to optimize patient safety and protocol adherence
UAN#: 0465-0000-25-130-H01-P
Presenter:
- Izabela Mazur
Description:
This session will cover the latest data in limited stage cancer and all the new updates in the 2nd line setting. Small cell lung cancer is an active area of research and there are several new updates that are changing the course of treatment. This also comes with new challenges for the community oncology practitioners as well as new toxicities. This session will dive into some of the mechanisms of action for these unique toxicities and adaptations for the new challenges.
Learning Objectives:
- Identify efficacy differences between agents
- Explain limitations in the clinical trials as they relate to the SCLC patient
- Describe the unique nature of toxicities related to newer agents in SCLC population
- State challenges that community oncologists face when prescribing newer therapies
Additional Information
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.